



Development of Hereditary Cancer Prevention Measures in Pskov Region

HeCaPrev

Priority 3 Promotion from people to people cooperation

Measure 3.2 Cooperation in sphere of culture, sport, education, social and health



Short summary of the project

Recently new and alternative methods for Hereditary Cancer (HC) management, mainly preventative in nature, have been introduced and are currently practiced to a high level in Latvia, meanwhile still lacking in Russia. Through this project, the researchers from Latvia - Hereditary Cancer Institute of Riga Stradins University (RSU) intend to transfer a broad spectrum of knowledge on HC to colleagues in Russia, Pskov Onkological Dispensary (POD). By doing so, the best available knowledge and HC management practices will become available to the colleagues in RU, and will be put to use during and long after this project to ensure the most up-to-date HC management in Pskov region.

Overall objective

Improvement of life quality in Russia and Latvia by developing effective population based hereditary cancer screening and management system model and combating hereditary cancer in border regions.

Specific objective


- ✚ to ensure information and experience exchange about HC, its preventative measures and management;
- ✚ to raise awareness on HC as manageable and curable disease among wider society of medics and general population of Pskov region;
- ✚ to identify high HC risk individuals through HC patient hospital and registry screening pilot projects and molecular investigations in Latvia and Russia;
- ✚ to develop HC prevention and management base in Pskov region by establishing Pskov hereditary cancer centre within POD and beginning of HC consultation and management activities in this newly established facility.

Beneficiary

Riga Stradins University (Riga, Latvia)

Partners

Pskov Onkological Dispensary (Pskov, Russia)





Expected results

- ✚ **HC data base** will be established, where during the project all the data from the pilot project will be assembled;
- ✚ **Program** which can calculate persons HC risk based on family cancer history surveys and DNA data (**investigations** will be carried out **in Latvia and Russia** equally) will be established and made compatible with the existing POD oncology disease patient data base. For Latvian partners who will be able to use the newly acquired data to complement their previous research data gathered in the Latvian and Estonian parts of the programme area during the previous CBC projects;
- ✚ Informational updates done for Latvian website and website developed in Russia;
- ✚ **POD employees** will learn **how to work** with HC patients and HC high-risk individuals and how to use equipment purchased during the project;
- ✚ The newly **established HC centre in Pskov** (including clinical part for providing consultations, preventive measures and treatment and molecular laboratory for carrying out diagnostic tests) is open to the HC patients and analyses are made and consultations are provided on a regular basis;
- ✚ Around 2,000 **doctors** and 20,000 **HC patients** and **high-risk patients** in Pskov region will have a better understanding of HC management;
- ✚ **General public** of Pskov region and Latvia (~20,000 people RU and 20,000 people in LV) will have a wider knowledge on HC.

Final beneficiaries

- ✚ **Medical personnel** involved in HC treatment
- ✚ **HC patients** and their relatives
- ✚ **General public**

Duration

24 months

Budget

Total budget: **297 176,00** EUR

Programme co-financing: 267 458,00 EUR (90%)

Project co-financing: 29 718,00 EUR (10%)

Contact Person

Ms.Ieva Ubele

ieva.ubele@rsu.lv / phone +371 26449426

